Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Dan Spillane who wrote (1359)	2/24/1999 5:37:00 PM
From: Anthony Wong	Respond to of 2539

Monsanto Halts Research on Two Experimental Cancer Medicines [this is old news, already reported on Feb. 11, see #reply-7772590] Bloomberg News February 24, 1999, 4:21 p.m. ET Monsanto Halts Research on Two Experimental Cancer Medicines St. Louis, Feb. 24 (Bloomberg) -- Monsanto Co. said it ended research on two experimental cancer drugs, one of which was in the last of three stages of testing required for U.S. approval. This is the second setback this year for Monsanto's research program. Last month, Monsanto said it ended development of two oral clot-preventing heart drugs that were in advanced testing. The setbacks come as Monsanto's new arthritis drug Celebrex has one of the best U.S. introductions ever for a new medicine. Celebrex captured more than 400,000 prescriptions in its first five weeks on the market. The drug seems to be less harsh on the stomach than older painkillers such as ibuprofen. Monsanto, based in St. Louis, rose 7/16 to 48. --Kerry Dooley in the Princeton newsroom (609) 279-4016/gfh